AIRSUPRA® (albuterol/budesonide) represents a paradigm shift in asthma rescue as the first and only FDA-approved anti-inflammatory rescue inhaler for asthma that is designed to address both ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved a pressurized metered-dose inhaler with a fixed-dose combination of albuterol and budesonide ...
Researchers have found that more than a quarter of asthma patients are still over-using inhalers intended for rapid relief of symptoms. Overuse of these inhalers is linked to an increased risk of ...
Please provide your email address to receive an email when new articles are posted on . The American College of Allergy, Asthma & Immunology (ACAAI) and American Academy of Allergy, Asthma & ...
Findings from a first-of-its-kind virtual trial in pulmonary medicine, conducted at Rutgers and many other institutions, suggest adding an inhaled corticosteroid to rescue therapy could sharply reduce ...
Why are we asking for donations? Why are we asking for donations? This site is free thanks to our community of supporters. Voluntary donations from readers like you keep our news accessible for ...
Positive full results from the BATURA Phase IIIb trial showed AstraZeneca’s anti-inflammatory reliever rescue therapy, AIRSUPRA (albuterol/budesonide), demonstrated statistically significant and ...
The Food and Drug Administration approved AstraZeneca and Avillion’s Airsupra (formerly PT027), as an asthma rescue treatment this week. The approval came after the results of the drug’s MANDALA and ...
AstraZeneca already has its aging two-drug inhaler Symbicort as a maintenance treatment for asthma. Now, with a pair of trial wins, the company looks on track to have a novel doublet for controlling ...
Tezspire (tezepelumab-ekko) is a monthly injection used to treat severe asthma. It was approved by the FDA in 2021 for use in addition to other asthma controlling medicines in people 12 and older.
WILMINGTON, Del.--(BUSINESS WIRE)--The Food and Drug Administration’s (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) has voted 16 to 1 that the data support a favorable benefit risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback